Search

Your search keyword '"Faivre-Chauvet, Alain"' showing total 335 results
Start Over Author "Faivre-Chauvet, Alain"
335 results on '"Faivre-Chauvet, Alain"'

3. Radioimmunotherapy of Lymphomas

Author

Bailly, Clément, Bodet-Milin, Caroline, Guerard, François, Chouin, Nicolas, Gaschet, Joelle, Cherel, Michel, Davodeau, François, Faivre-Chauvet, Alain, Kraeber-Bodéré, Françoise, Bourgeois, Mickaël, and Giovanella, Luca, editor

Published
2019
Full Text
View/download PDF

5. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Author

Alves, Francisco, Antunes, Inês F., Cazzola, Emiliano, Cleeren, Frederik, Cornelissen, Bart, Denkova, Antonia, Engle, Jonathan, Faivre-Chauvet, Alain, Gillings, Nic, Hendrikx, Jeroen J. M. A., Jalilian, Amir R., van der Meulen, Nicholas P., Mikolajczak, Renata, Neels, Oliver C., Pillai, Maroor R. A., Reilly, Raymond, Rubow, Sietske, Seimbille, Yann, Spreckelmeyer, Sarah, Szymanski, Wiktor, and Taddei, Carlotta

Published
2021
Full Text
View/download PDF

7. Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma

Author

Métivier, Cassandra, primary, Le Saëc, Patricia, additional, Gaschet, Joëlle, additional, Chauvet, Catherine, additional, Marionneau-Lambot, Séverine, additional, Hofgaard, Peter O., additional, Bogen, Bjarne, additional, Pineau, Julie, additional, Le Bris, Nathalie, additional, Tripier, Raphaël, additional, Alliot, Cyrille, additional, Haddad, Férid, additional, Chérel, Michel, additional, Chouin, Nicolas, additional, Faivre-Chauvet, Alain, additional, and Rbah-Vidal, Latifa, additional

Published
2023
Full Text
View/download PDF

8. New Advances in Radioimmunotherapy for the Treatment of Cancers

Author

Kraeber-Bodéré, Françoise, Bodet-Milin, Caroline, Rousseau, Caroline, Carlier, Thomas, Ferrer, Ludovic, Chouin, Nicolas, Haddad, Férid, Davodeau, François, Chatal, Jean-François, Faivre-Chauvet, Alain, Gestin, Jean-François, Chérel, Michel, Barbet, Jacques, and Rezaei, Nima, editor

Published
2015
Full Text
View/download PDF

12. [68Ga]Ga‐PentixaFor: Development of a fully automated in hospital production on the Trasis miniAllinOne synthesizer.

Author

Costes, Julien, Casasagrande, Kilian, Dubegny, Constance, Castillo, Juan, Kaufman, Jens, Masset, Julien, Vriamont, Charles, Warnier, Corentin, Faivre‐Chauvet, Alain, and Delage, Judith Anna

Subjects
QUALITY control, ENVIRONMENTAL monitoring, RADIOACTIVE tracers, HOSPITALS, CARDIOVASCULAR diseases
Abstract

[68Ga]Ga‐PentixaFor is a frequently used radiotracer to image the CXCR4/CXCL12 axis in various malignancies, infections, and cardiovascular diseases. To answer increasing clinical needs, an automatized synthesis process ensuring efficient and reproducible production and improving operator's radioprotection is needed. [68Ga]Ga‐PentixaFor synthesis has been described on other synthesizers but not on the miniAiO. In this work, we defined automated synthesis process and an analytical method for the quality control of [68Ga]Ga‐PentixaFor. Validation batches were performed under aseptic conditions in a class A hotcell. All the quality controls required by the European Pharmacopea (Eur. Ph) were performed. The analytical methods were validated according to the International Conference Harmonization (ICH) recommendations. Validation batches were performed with a radiochemical yield of 94.8 ± 2.6%. All the quality controls were in conformity with the Eur. Ph, and the validation of the analytical method complied with the ICH. The environmental monitoring performed during the synthesis process showed that the aseptic conditions were ensured. [68Ga]Ga‐PentixaFor was successfully synthesized with the miniAiO by a fully automated process. This robust production mode and the quality control have been validated in this study allowing to increase the access of patients to this new promising radiopharmaceutical. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Highly inert Cu(ii) complexes of C-aryl bifunctional cyclam-picolinates with remarkable 64Cu-labelling and biodistribution

Author

Pineau, Julie, primary, Lima, Luís M. P., additional, Le Roy, Marie M., additional, Marionneau-Lambot, Séverine, additional, Cordier, Marie, additional, Le Saëc, Patricia, additional, Zeevaart, Jan Rijn, additional, Driver, Cathryn H. S., additional, Faivre-Chauvet, Alain, additional, Le Bris, Nathalie, additional, and Tripier, Raphaël, additional

Published
2023
Full Text
View/download PDF

14. 90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study

Author

Chevallier, Patrice, Eugene, Thomas, Robillard, Nelly, Isnard, Françoise, Nicolini, Franck, Escoffre-Barbe, Martine, Huguet, Françoise, Hunault, Mathilde, Marcais, Antoine, Gaschet, Joelle, Cherel, Michel, Guillaume, Thierry, Delaunay, Jacques, Peterlin, Pierre, Eveillard, Marion, Thomas, Xavier, Ifrah, Norbert, Lapusan, Simona, Bodet-Milin, Caroline, Barbet, Jacques, Faivre-Chauvet, Alain, Ferrer, Ludovic, Bene, Marie C, Le Houerou, Claire, Goldenberg, David M, Wegener, William A, and Kraeber-Bodéré, Françoise

Published
2015
Full Text
View/download PDF

15. Radiopharmaceutical good practices: Regulation between hospital and industry

Author

Faivre-Chauvet, Alain, Bourdeau, Cécile, and Bourgeois, Mickaël

Abstract

Radiopharmaceutical practices are divided into large-scale industrial manufacturing and small-scale “in-house” hospital radiopharmacy unit. The recent evolution of nuclear medicine involves deep consequences in this ever-present regulatory state, and hospital radiopharmacy units cannot be considered as contract manufacturing organizations (CMO). This review provides an updated status report of the official (and non-official) guidelines supporting the regulations required to meet hospital and industry common radiopharmaceutical manufacturing standards to facilitate the current and future innovative radiopharmaceutical development.

Published
2022

16. Antitumor Immunity Induced after α Irradiation

Author

Gorin, Jean-Baptiste, Ménager, Jérémie, Gouard, Sébastien, Maurel, Catherine, Guilloux, Yannick, Faivre-Chauvet, Alain, Morgenstern, Alfred, Bruchertseifer, Frank, Chérel, Michel, Davodeau, François, and Gaschet, Joëlle

Published
2014
Full Text
View/download PDF

17. Preclinical Evaluation of a 64 Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma.

Author

Métivier, Cassandra, Le Saëc, Patricia, Gaschet, Joëlle, Chauvet, Catherine, Marionneau-Lambot, Séverine, Hofgaard, Peter O., Bogen, Bjarne, Pineau, Julie, Le Bris, Nathalie, Tripier, Raphaël, Alliot, Cyrille, Haddad, Férid, Chérel, Michel, Chouin, Nicolas, Faivre-Chauvet, Alain, and Rbah-Vidal, Latifa

Subjects
MULTIPLE myeloma, POSITRON emission tomography, TUMOR markers, MEDICAL dosimetry, NUCLEAR medicine, PROTEIN microarrays, RADIOISOTOPES
Abstract

Although the concept of theranostics is neither new nor exclusive to nuclear medicine, it is a particularly promising approach for the future of nuclear oncology. This approach is based on the use of molecules targeting specific biomarkers in the tumour or its microenvironment, associated with optimal radionuclides which, depending on their emission properties, allow the combination of diagnosis by molecular imaging and targeted radionuclide therapy (TRT). Copper-64 has suitable decay properties (both β+ and β- decays) for PET imaging and potentially for TRT, making it both an imaging and therapy agent. We developed and evaluated a theranostic approach using a copper-64 radiolabelled anti-CD138 antibody, [64Cu]Cu-TE1PA-9E7.4 in a MOPC315.BM mouse model of multiple myeloma. PET imaging using [64Cu]Cu-TE1PA-9E7.4 allows for high-resolution PET images. Dosimetric estimation from ex vivo biodistribution data revealed acceptable delivered doses to healthy organs and tissues, and a very encouraging tumour absorbed dose for TRT applications. Therapeutic efficacy resulting in delayed tumour growth and increased survival without inducing major or irreversible toxicity has been observed with 2 doses of 35 MBq administered at a 2-week interval. Repeated injections of [64Cu]Cu-TE1PA-9E7.4 are safe and can be effective for TRT application in this syngeneic preclinical model of MM. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. From bench to bedside: 64Cu/177Lu 1C1m-Fc anti TEM-1: mice-to-human dosimetry extrapolations for future theranostic applications.

Author

Gnesin, Silvano, Chouin, Nicolas, Cherel, Michel, Dunn, Steven Mark, Schaefer, Niklaus, Faivre-Chauvet, Alain, Prior, John O., and Delage, Judith Anna

Subjects
MEDICAL dosimetry, ABSORBED dose, NUCLEAR medicine, EXTRAPOLATION, COPPER, COMPANION diagnostics, POSITRON emission tomography
Abstract

The development of diagnostic and therapeutic radiopharmaceuticals is an hot topic in nuclear medicine. Several radiolabeled antibodies are under development necessitating both biokinetic and dosimetry extrapolations for effective human translation. The validation of different animal-to-human dosimetry extrapolation methods still is an open issue. This study reports the mice-to-human dosimetry extrapolation of 64Cu/177Lu 1C1m-Fc anti-TEM-1 for theranostic application in soft-tissue sarcomas. We adopt four methods; direct mice-to-human extrapolation (M1); dosimetry extrapolation considering a relative mass scaling factor (M2), application of a metabolic scaling factor (M3) and combination of M2 and M3 (M4). Predicted in-human dosimetry for the [64Cu]Cu-1C1m-Fc resulted in an effective dose of 0.05 mSv/MBq. Absorbed dose (AD) extrapolation for the [177Lu]Lu-1C1m-Fc indicated that the AD of 2 Gy and 4 Gy to the red-marrow and total-body can be reached with 5–10 GBq and 25–30 GBq of therapeutic activity administration respectively depending on applied dosimetry method. Dosimetry extrapolation methods provided significantly different absorbed doses in organs. Dosimetry properties for the [64Cu]Cu-1C1m-Fc are suitable for a diagnostic in-human use. The therapeutic application of [177Lu]Lu-1C1m-Fc presents challenges and would benefit from further assessments in animals' models such as dogs before moving into the clinic. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Development and in vitro evaluation of a copper-64 radiolabeled antibody for targeting the CXCR4 receptor in human multiple myeloma

Author

Métivier, Cassandra, primary, Le Saec, Patricia, additional, Bouhsine, Hela, additional, Marionneau-Lambot, Séverine, additional, Garçion, Emmanuel, additional, Tripier, Raphaël, additional, Haddad, Ferid, additional, Chérel, Michel, additional, Faivre-Chauvet, Alain, additional, and Rbah-Vidal, Latifa, additional

Published
2022
Full Text
View/download PDF

21. Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety

Author

Delage, Judith Anna, primary, Gnesin, Silvano, additional, Prior, John O., additional, Barbet, Jacques, additional, Le Saëc, Patricia, additional, Marionneau-Lambot, Séverine, additional, Gouard, Sébastien, additional, Chérel, Michel, additional, Bourgeois, Mickael, additional, Schaefer, Niklaus, additional, Viertl, David, additional, Fierle, Julie Katrin, additional, Dunn, Steven Mark, additional, and Faivre-Chauvet, Alain, additional

Published
2021
Full Text
View/download PDF

22. Highly inert Cu(II) complexes of C-aryl bifunctional cyclam-picolinates with remarkable 64Cu-labelling and biodistribution.

Author

Pineau, Julie, Lima, Luís M. P., Le Roy, Marie M., Marionneau-Lambot, Séverine, Cordier, Marie, Le Saëc, Patricia, Zeevaart, Jan Rijn, Driver, Cathryn H. S., Faivre-Chauvet, Alain, Le Bris, Nathalie, and Tripier, Raphaël

Subjects
COPPER, CARBOXYL group, CHEMICAL properties, NUCLEAR medicine, IMMUNOGLOBULINS, LIGANDS (Chemistry), CHELATING agents
Abstract

Cyclam-picolinate chelators were functionalized via click chemistry with an additional carboxyl group for subsequent bioconjugation to antibodies or for the modification of the overall charge of the corresponding 64Cu-radiocomplexes. The C-aryl functionalization strategy developed here preserves the chemical properties of the radiocomplexes whilst deeply enhancing their applications within nuclear medicine. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. New Advances in Radioimmunotherapy for the Treatment of Cancers

Author

Kraeber-Bodéré, Françoise, primary, Bodet-Milin, Caroline, additional, Rousseau, Caroline, additional, Carlier, Thomas, additional, Ferrer, Ludovic, additional, Chouin, Nicolas, additional, Haddad, Férid, additional, Davodeau, François, additional, Chatal, Jean-François, additional, Faivre-Chauvet, Alain, additional, Gestin, Jean-François, additional, Chérel, Michel, additional, and Barbet, Jacques, additional

Published
2014
Full Text
View/download PDF

24. Investigation on the reactivity of nucleophilic radiohalogens with arylboronic acids in water: access to an efficient single-step method for the radioiodination and astatination of antibodies

Author

Berdal, Marion, Gouard, Sébastien, Eychenne, Romain, Marionneau-Lambot, Séverine, Croyal, Mikaël, Faivre-Chauvet, Alain, Chérel, Michel, Gaschet, Joëlle, Gestin, Jean-François, Guérard, François, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), GIP ARRONAX [Nantes] (Saint-Herblain), Université de Nantes (UN), Mass Spectrometry Core Facility [Nantes] (CRNH-O ), Physiopathologie des Adaptations Nutritionnelles (PhAN), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de Médecine Nucléaire [Nantes], Hôpital Laennec, CRLCC René Gauducheau, INCa-DGOS-Inserm_12558, ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), ANR-16-IDEX-0007,NExT (I-SITE),NExT (I-SITE)(2016), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Nutrition Humaine Ouest (CRNH Ouest), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Bernardo, Elizabeth, Nucléaire pour la Santé - - ARRONAXPLUS2011 - ANR-11-EQPX-0004 - EQPX - VALID, Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID, and NExT (I-SITE) - - NExT (I-SITE)2016 - ANR-16-IDEX-0007 - IDEX - VALID

Subjects
Biodistribution, medicine.drug_class, [SDV]Life Sciences [q-bio], Single step, [SDV.CAN]Life Sciences [q-bio]/Cancer, 010402 general chemistry, Monoclonal antibody, 01 natural sciences, Nucleophile, [SDV.CAN] Life Sciences [q-bio]/Cancer, Labelling, medicine, Reactivity (chemistry), biology, 010405 organic chemistry, Chemistry, [CHIM.ORGA]Chemical Sciences/Organic chemistry, General Chemistry, [CHIM.ORGA] Chemical Sciences/Organic chemistry, Combinatorial chemistry, 6. Clean water, 0104 chemical sciences, 3. Good health, [SDV] Life Sciences [q-bio], biology.protein, Antibody, Divergent synthesis
Abstract

Easy access to radioiodinated and 211At-labelled bio(macro)molecules is essential to develop new strategies in nuclear imaging and targeted radionuclide therapy of cancers. Yet, the labelling of complex molecules with heavy radiohalogens is often poorly effective due to the multiple steps and intermediate purifications needed. Herein, we investigate the potential of arylboron chemistry as an alternative approach for the late stage labelling of antibodies. The reactivity of a model precursor, 4-chlorobenzeneboronic acid (1) with nucleophilic iodine-125 and astatine-211 was at first investigated in aqueous conditions. In the presence of a copper(ii) catalyst and 1,10-phenanthroline, quantitative radiochemical yields (RCYs) were achieved within 30 minutes at room temperature. The optimum conditions were then applied to a CD138 targeting monoclonal antibody (mAb) that has previously been validated for imaging and therapy in a preclinical model of multiple myeloma. RCYs remained high (>80% for 125I-labelling and >95% for 211At-labelling), and the whole procedure led to increased specific activities within less time in comparison with previously reported methods. Biodistribution study in mice indicated that targeting properties of the radiolabelled mAb were well preserved, leading to a high tumour uptake in a CD138 expressing tumour model. The possibility of divergent synthesis from a common modified carrier protein demonstrated herein opens facilitated perspectives in radiotheranostic applications with the radioiodine/211At pairs. Overall, the possibility to develop radiolabelling kits offered by this procedure should facilitate its translation to clinical applications., The high reactivity of astatine and iodine in water with arylboronic acids provides access to an efficient single-step antibody radiolabelling.

Published
2021

25. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Author

Alves, Francisco (author), Antunes, Inês F. (author), Cazzola, Emiliano (author), Cleeren, Frederik (author), Cornelissen, Bart (author), Denkova, A.G. (author), Engle, Jonathan (author), Faivre-Chauvet, Alain (author), Seimbille, Y. (author), Alves, Francisco (author), Antunes, Inês F. (author), Cazzola, Emiliano (author), Cleeren, Frederik (author), Cornelissen, Bart (author), Denkova, A.G. (author), Engle, Jonathan (author), Faivre-Chauvet, Alain (author), and Seimbille, Y. (author)

Abstract

Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Results: This commentary of highlights has resulted in 21 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals. Also the first contribution in relation to MRI-agents is included. Conclusions: Trends in (radio)chemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry., RST/Applied Radiation & Isotopes

Published
2021
Full Text
View/download PDF

31. Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study

Author

Bodet-Milin, Caroline, primary, Faivre-Chauvet, Alain, additional, Carlier, Thomas, additional, Ansquer, Catherine, additional, Rauscher, Aurore, additional, Frampas, Eric, additional, Toulgoat, Frederique, additional, Masson, Damien, additional, Bourgeois, Mickael, additional, Cerato, Evelyne, additional, Rohmer, Vincent, additional, Couturier, Olivier, additional, Drui, Delphine, additional, Goldenberg, David M., additional, Sharkey, Robert M., additional, Barbet, Jacques, additional, and Kraeber-Bodere, Francoise, additional

Published
2021
Full Text
View/download PDF

32. Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in HER2-negative Breast Cancer

Author

Rousseau, Caroline, Goldenberg, David, Colombié, Mathilde, Sébille, Jean-Charles, Meingan, Philippe, Ferrer, Ludovic, Baumgartner, Pierre, Cerato, Evelyne, Masson, Damien, Campone, Mario, Rauscher, Aurore, Fleury, Vincent, Labbé, Catherine, Faivre-Chauvet, Alain, Fresnel, Jean-Sebastien, Toquet, Claire, Barbet, Jacques, Sharkey, Robert, Campion, Loïc, Kraeber-Bodéré, Françoise, Bernardo, Elizabeth, Nucléaire pour la Santé - - ARRONAXPLUS2011 - ANR-11-EQPX-0004 - EQPX - VALID, Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), IBC Pharmaceuticals Inc [Morris Plains, NJ, USA], Immunomedics Inc. [Morris Plains, NJ, USA], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Service de Médecine Nucléaire [Nantes], Hôpital Laennec, Service de Radiologie [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Physique [Nantes] (GIP Arronax), ARRONAX - (GIP) Groupement d'Intérêt Public [Saint-Herblain] (Institut de Recherche Public), PHU 11 Pharmacie [CHU Nantes] (Pharmacie Centrale), Délégation à la Recherche Clinique et à l'Enovation [Nantes] ((DRCI)), Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Biologie des Cancers [ICO, Nantes], UNICANCER-UNICANCER, Institut d'oncologie de l'Ouest [CHU Nantes], Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Pathologie [CHU Nantes], Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Plateforme de Biométrie [CHU Nantes] (Hôtel Dieu), Supported in part by grants from the University Hospital of Nantes and Fondation Avenir in 2010, the French National Agency for Research, called 'Investissements d’Avenir' IRON Labex ANR-11-LABX-0018-01 and ArronaxPlus Equipex ANR-11-EQPX-0004 and by a grant INCa-DGOS-Inserm_12558 (SIRIC ILIAD)., ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), Oncologie nucléaire (CRCINA - Département NOHMAD - Equipe 13), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Institut de cancérologie de l'Ouest - Nantes (ICO Nantes), CRLCC Paul Papin-CRLCC René Gauducheau, Institut de Cancérologie de l'Ouest, Integrative oncogenomics of multiple myeloma pathogenesis and progression (CRCINA - Département NOHMAD - Equipe 11), ANR-11-EQPX-0004/11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), ANR-11-LABX-0018/11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)

Subjects
bispecific antibody, Breast cancer, [SDV.CAN] Life Sciences [q-bio]/Cancer, PET/CT, gallium-68, Immuno-PET, pretargeting, [SDV.CAN]Life Sciences [q-bio]/Cancer, Oncology: Breast, Radioimmunoimaging
Abstract

International audience; Purpose: This prospective study evaluated the imaging performance of a novel immunological pretargeting positron-emission tomorgraphy (immuno-PET) method in patients with HER2-negative, carcinoembryonic antigen (CEA)-positive, metastatic breast cancer (BC), compared to computed tomography (CT), bone magnetic resonance imaging (MRI), and 18Fluorodeoxyglucose PET (FDG-PET). Patients and Methods: Twenty-three patients underwent whole-body immuno-PET after injection of 150 MBq 68Ga-IMP288, a histamine-succinyl-glycine peptide given following initial targeting of a trivalent anti-CEA, bispecific, anti-peptide antibody. The gold standards were histology and imaging follow-up. Tumor standard uptake values (SUVmax and SUVmean) were measured, and tumor burden analyzed using Total Tumor Volume (TTV) and Total Lesion Activity (TLA). Results: Total lesion sensitivity of immuno-PET and FDG-PET was 94.7% (1116/1178) and 89.6% (1056/1178), respectively. Immuno-PET had a somewhat higher sensitivity than CT and FDG-PET in lymph nodes (92.4% vs 69.7% and 89.4%, respectively) and liver metastases (97.3% vs 92.1% and 94.8%, respectively), whereas sensitivity was lower for lung metastases (48.3% vs 100% and 75.9%, respectively). Immuno-PET showed higher sensitivity than MRI and FDG-PET for bone lesions (95.8% vs 90.7% and 89.3%, respectively). In contrast to FDG-PET, immuno-PET disclosed brain metastases. Despite equivalent tumor SUVmax, SUVmean, and TTV, TLA was significantly higher with immuno-PET compared to FDG PET (P = 0.009). Conclusion: Immuno-PET using anti-CEA/anti-IMP288 bispecific antibody, followed by 68Ga-IMP288, is a potentially sensitive theranostic imaging method for HER2-negative, CEA-positive, metastatic BC patients, and warrants further research.

Published
2020

33. Radionuclide Metabolic Therapy

Author

Mantel, Eleanor S., additional, Williams, Jessica, additional, Szczepura, Katy, additional, Sjögreen Gleisner, Katarina, additional, Strigari, Lidia, additional, Flux, Glenn, additional, Larg, Maria Iulia, additional, Testanera, Giorgio, additional, Chiti, Arturo, additional, Piciu, Doina, additional, Menghis, Ruth Berhane, additional, Lowry, Brian A., additional, Mayes, Christopher, additional, Vinjamuri, Sobhan, additional, Silva, Nadine, additional, do Rosário Vieira, Maria, additional, Rauscher, Aurore, additional, Bodet-Milin, Caroline, additional, Faivre-Chauvet, Alain, additional, Pallardy, Amandine, additional, Kraeber-Bodéré, Françoise, additional, Gorgan, Ana, additional, Lupu, Nicoleta, additional, and Cutler, Cathy S., additional

Published
2013
Full Text
View/download PDF

36. Cyclam-Based Chelators Bearing Phosphonated Pyridine Pendants for 64Cu-PET Imaging: Synthesis, Physicochemical Studies, Radiolabeling, and Bioimaging

Author

Knighton, Richard C., primary, Troadec, Thibault, additional, Mazan, Valérie, additional, Le Saëc, Patricia, additional, Marionneau-Lambot, Séverine, additional, Le Bihan, Thomas, additional, Saffon-Merceron, Nathalie, additional, Le Bris, Nathalie, additional, Chérel, Michel, additional, Faivre-Chauvet, Alain, additional, Elhabiri, Mourad, additional, Charbonnière, Loïc J., additional, and Tripier, Raphaël, additional

Published
2021
Full Text
View/download PDF

37. Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [177Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model

Author

Delage, Judith Anna, primary, Faivre-Chauvet, Alain, additional, Barbet, Jacques, additional, Fierle, Julie Katrin, additional, Schaefer, Niklaus, additional, Coukos, George, additional, Viertl, David, additional, Dunn, Steven Mark, additional, Gnesin, Silvano, additional, and Prior, John O., additional

Published
2021
Full Text
View/download PDF

38. Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors

Author

Ansquer, Catherine, primary, Touchefeu, Yann, additional, Faivre-Chauvet, Alain, additional, Leux, Christophe, additional, Le Bras, Maëlle, additional, Régenet, Nicolas, additional, Fleury, Vincent, additional, Maucherat, Bruno, additional, Senellart, Hélène, additional, Guyetant, Serge, additional, Carlier, Thomas, additional, Scotet-Cérato, Evelyne, additional, Rauscher, Aurore, additional, Frampas, Eric, additional, and Kraeber-Bodéré, Françoise, additional

Published
2020
Full Text
View/download PDF

39. Cyclam-Based Chelators Bearing Phosphonated Pyridine Pendants for 64Cu-PET Imaging : Synthesis, Physico-Chemical Studies, Radiolabeling and Bioimaging.

Author

Knighton, Richard, primary, Troadec, Thibault, primary, Mazan, Valerie, primary, La Saëc, Patricia, primary, Marionneau-Lambot, Séverine, primary, Le Bihan, Thomas, primary, Saffon-Merceron, Nathalie, primary, Le Bris, Nathalie, primary, Chérel, Michel, primary, Faivre-Chauvet, Alain, primary, Elhabiri, Mourad, primary, Charbonnière, Loïc J., primary, and Tripier, Raphael, primary

Published
2020
Full Text
View/download PDF

40. Radiolabeled Antibodies for Cancer Imaging and Therapy

Author

Barbet, Jacques, primary, Bardiès, Manuel, additional, Bourgeois, Mickael, additional, Chatal, Jean-François, additional, Chérel, Michel, additional, Davodeau, François, additional, Faivre-Chauvet, Alain, additional, Gestin, Jean-François, additional, and Kraeber-Bodéré, Françoise, additional

Published
2012
Full Text
View/download PDF

45. Cell Tracking in Cancer Immunotherapy

Author

Perrin, Justine, primary, Capitao, Marisa, additional, Mougin-Degraef, Marie, additional, Guérard, François, additional, Faivre-Chauvet, Alain, additional, Rbah-Vidal, Latifa, additional, Gaschet, Joëlle, additional, Guilloux, Yannick, additional, Kraeber-Bodéré, Françoise, additional, Chérel, Michel, additional, and Barbet, Jacques, additional

Published
2020
Full Text
View/download PDF

46. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model

Author

Bailly, Clément, Gouard, Sébastien, Guérard, François, Chalopin, Benjamin, Carlier, Thomas, Faivre-Chauvet, Alain, Saëc, Patricia Remaud-Le, Bourgeois, Mickaël, Chouin, Nicolas, Rbah-Vidal, Latifa, Tripier, Raphaël, Haddad, Ferid, Kraeber-Bodéré, Françoise, Bodet-Milin, Caroline, Chérel, Michel, Service de Médecine Nucléaire [Nantes], Hôpital Laennec, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), ARRONAX - (GIP) Groupement d'Intérêt Public [Saint-Herblain] (Institut de Recherche Public), Ecole Nationale Vétérinaire, Agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS), Chimie, Electrochimie Moléculaires et Chimie Analytique (CEMCA), Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Nuclear Medicine Department, and ICO-René Gauducheau Cancer Center

Subjects
lcsh:Chemistry, copper-64, multiple myeloma, lcsh:Biology (General), lcsh:QD1-999, [CHIM.ORGA]Chemical Sciences/Organic chemistry, zirconium-89, immuno-PET, murine CD138, [CHIM.COOR]Chemical Sciences/Coordination chemistry, lcsh:QH301-705.5, [CHIM.RADIO]Chemical Sciences/Radiochemistry
Abstract

Although positron emission tomography (PET) imaging with 18-Fluorodeoxyglucose (18F-FDG) is a promising technique in multiple myeloma (MM), the development of other radiopharmaceuticals seems relevant. CD138 is currently used as a standard marker for the identification of myeloma cells and could be used in phenotype tumor imaging. In this study, we used an anti-CD138 murine antibody (9E7.4) radiolabeled with copper-64 (64Cu) or zirconium-89 (89Zr) and compared them in a syngeneic mouse model to select the optimal tracers for MM PET imaging. Then, 9E7.4 was conjugated to TE2A-benzyl isothiocyanate (TE2A) and desferrioxamine (DFO) chelators for 64Cu and 89Zr labeling, respectively. 64Cu-TE2A-9E7.4 and 89Zr-DFO-9E7.4 antibodies were evaluated by PET imaging and biodistribution studies in C57BL/KaLwRij mice bearing either 5T33-MM subcutaneous tumors or bone lesions and were compared to 18F-FDG-PET imaging. In biodistribution and PET studies, 64Cu-TE2A-9E7.4 and 89Zr-DFO-9E7.4 displayed comparable good tumor uptake of subcutaneous tumors. On the bone lesions, PET imaging with 64Cu-TE2A-9E7.4 and 89Zr-DFO-9E7.4 showed higher uptake than with 18F-FDG-PET. Comparison of both 9E7.4 conjugates revealed higher nonspecific bone uptakes of 89Zr-DFO-9E7.4 than 64Cu-TE2A-9E7.4. Because of free 89Zr&rsquo, s tropism for bone when using 89Zr-anti-CD138, 64Cu-anti-CD138 antibody had the most optimal tumor-to-nontarget tissue ratios for translation into humans as a specific new imaging radiopharmaceutical agent in MM.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results